TONGHUA DONGBAO PHARMACEUTICAL CO., LTD.

Autres langues Tonghua Dongbao Pharmaceutical Co., Ltd.

Actions

600867

CNE000000H87

Cours en clôture Shanghai S.E. Autres places de cotation 00:00:00 26/04/2024			Varia. 5j.	Varia. 1 janv.
10,59 ^CNY	+4,03 %		+5,58 %	-2,22 %

29/03	Les bénéfices de Dongbao Pharma en 2023 chutent de 26 %	MT
29/01	Tonghua Dongbao Pharmaceutical Co. publie ses résultats pour l'exercice clos le 31 décembre 2023	CI

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Dongbao Pharma's 2023 Profit Drops 26%	29/03
Tonghua Dongbao Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	29/01
Dongbao Pharma Unit's Gout Drug Clinical Study Achieves Primary Endpoint	17/01
Dongbao Pharmaceutical's Unit Gets Nod to Trial Diabetes Drug	27/12
Dongbao Pharmaceutical Unit Gets Nod to Trial Diabetes Drug	12/12
Tonghua Dongbao Pharma Unit Enrolls First Subject for Clinical Trial of Diabetes Drug	06/12
Tonghua Dongbao Pharma Registers Diabetes Drug	05/12
Tonghua Dongbao Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023	30/10/23
Tonghua Dongbao Pharmaceutical's Insulin Injection Shows Positive Results in German Trial	24/10/23
Adocia Announces its Partner Tonghua Dongbao Releases Positive Results on the Three Clinical Studies Conducted on BioChaperone Combo THDB0207 Formulation Containing Insulin Glargine and Insulin Lispro from Tonghua Dongbao	23/10/23
Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd. Announces an Exclusive Licensing Agreement with Tonghua Dongbao Pharmaceutical Co., Ltd. to Commercialize Three Insulin Biosimilars - Insulin Aspart, Insulin Lispro, and Insulin Glargine in the U.S	21/09/23
Tonghua Dongbao Pharmaceutical Co., Ltd.(XSSC:600867) added to S&P Global BMI Index	18/09/23
Tonghua Dongbao Pharmaceutical Co., Ltd.(XSSC:600867) added to FTSE All-World Index	18/09/23
Tonghua Dongbao Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023	21/08/23
Tonghua Dongbao Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	26/04/23
Tonghua Dongbao Pharmaceutical Enrolls First Subject for Phase II Trial of Gout Drug; Shares Rose 4%	08/02/23
Tonghua Dongbao Pharma’s Net Profit Jumps 21% Despite Revenue Drop	07/02/23
Tonghua Dongbao Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022	06/02/23
Tonghua Dongbao Pharma Wins Nod to Trial Drug Against Uric Acid, Gout	23/12/22
Tonghua Dongbao Gets Regulatory Approval For Two Insulin Injections	16/11/22

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Tonghua Dongbao Pharmaceutical Co., Ltd.

Actions

600867

CNE000000H87

Autres langues

Filtres